New pill combo aims to fight tough blood cancer
NCT ID NCT06769490
Summary
This early-stage trial is testing the safety and best dose of a new two-drug oral combination (ziftomenib + quizartinib) for adults with a specific type of acute myeloid leukemia (AML) that has returned or not responded to prior treatment. The main goal is to see if the combination is safe and tolerable, while also looking for early signs that it might help control the cancer. It is enrolling 44 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Texas M. D. Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.